AdultPediatricGeriatricDosage Forms & Strengths tablet 5mg 10mg suppository 25mg injectable solution 5mg/mL Severe Nausea & Vomiting PO: Immediate-release, 5-10 mg q6-8hr; extended-release, 10 mg q12hr or 15 mg every morning Suppository: 25 mg q12hr IM: 5-10 mg q3-4hr; not to exceed 40 mg/day IV: 2.5-10 mg q3-4hr; not to exceed 10 mg/dose or 40 mg/day Severe Intraoperative Nausea & Vomiting Prophylaxis IM: 5-10 mg administered 1-2 hours before induction of anesthesia; may be repeated once 30 minutes after initial dose IV: 5-10 mg administered 15-30 minutes before induction of anesthesia, repeated once before procedure if desired, or 20 mg/L administered 15-30 minutes before induction; not to exceed 30 mg/day Psychosis 5-10 mg PO q6-8hr; slowly titrate dose q2-3days; not to exceed 150 mg/day 10-20 mg IM q2-4hr to gain control; 3-4 doses rarely neededDosage Forms & Strengths tablet 5mg 10mg suppository 2.5mg 5mg 25mg injectable solution 5mg/mL Psychotic Disorder <2 years: Not recommended 2-6 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 20 mg/day; not to exceed 10 mg on the first day 6-12 years: 2.5 mg PO/PR q8-12hr initially; not to exceed 25 mg/day; not to exceed 10 mg on the first day Severe Nausea & Vomiting <2 years: Not recommended ≥2 years (9-13 kg): 2.5 mg PO daily or q12hr; not to exceed 7.5 mg/day ≥2 years (13.1-18 kg): 2.5 mg PO q8-12hr; not to exceed 10 mg/day ≥2 years (18.1-37 kg): 2.5 mg PO q8hr or 5 mg PO q12hr; not to exceed 15 mg/dayNot drug of choice in elderly, because of extrapyramidal symptoms Nonpsychotic Dementia Behavior (Off-label) Lower initial dose and adjust gradually; 2.5-5 mg/day PO; dosing interval may be increased to q8-12hr PRN; not to exceed 75 mg/dayInteraction CheckerEnter a drug name and prochlorperazineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (10)amisulprideamisulpride, prochlorperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.disopyramideprochlorperazine and disopyramide both increase QTc interval. Contraindicated.ibutilideprochlorperazine and ibutilide both increase QTc interval. Contraindicated.indapamideprochlorperazine and indapamide both increase QTc interval. Contraindicated.metrizamideprochlorperazine, metrizamide. Mechanism: unknown. Contraindicated. Risk of seizure. D/C phenothiazine 24h before admin. of metrizamide.pentamidineprochlorperazine and pentamidine both increase QTc interval. Contraindicated.pimozideprochlorperazine and pimozide both increase QTc interval. Contraindicated.procainamideprochlorperazine and procainamide both increase QTc interval. Contraindicated.quinidineprochlorperazine and quinidine both increase QTc interval. Contraindicated.sotalolprochlorperazine and sotalol both increase QTc interval. Contraindicated.Serious - Use Alternative (69)aminolevulinic acid oralaminolevulinic acid oral, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.aminolevulinic acid topicalprochlorperazine increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.amiodaroneprochlorperazine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.apomorphineprochlorperazine decreases effects of apomorphine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.arsenic trioxideprochlorperazine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrineprochlorperazine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.benzhydrocodone/acetaminophenbenzhydrocodone/acetaminophen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).benzhydrocodone/acetaminophen and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebromocriptineprochlorperazine decreases effects of bromocriptine by pharmacodynamic antagonism. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine transdermalbuprenorphine transdermal and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatebuprenorphine, long-acting injectionbuprenorphine, long-acting injection and prochlorperazine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequatecabergolineprochlorperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated.calcium/magnesium/potassium/sodium oxybatesprochlorperazine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.chlorpromazinechlorpromazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.clarithromycinprochlorperazine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.degarelixdegarelix and prochlorperazine both decrease QTc interval. Avoid or Use Alternate Drug.dofetilideprochlorperazine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.dopamineprochlorperazine decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.dosulepinprochlorperazine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.dronedaroneprochlorperazine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.droperidolprochlorperazine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.epinephrineepinephrine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.epinephrine racemicepinephrine racemic and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.erythromycin baseprochlorperazine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateprochlorperazine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateprochlorperazine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateprochlorperazine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.fentanylfentanyl, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl intranasalfentanyl intranasal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transdermalfentanyl transdermal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fentanyl transmucosalfentanyl transmucosal, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration with other CNS depressants, such as skeletal muscle relaxants, may cause respiratory depression, hypotension, profound sedation, coma, and/or death. Consider dose reduction of either or both agents to avoid serious adverse effects. Monitor for hypotension, respiratory depression, and profound sedation.fluconazoleprochlorperazine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.fluphenazinefluphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.formoterolprochlorperazine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.haloperidolprochlorperazine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.hydrocodonehydrocodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).itraconazoleprochlorperazine and itraconazole both increase QTc interval. Avoid or Use Alternate Drug.ketoconazoleprochlorperazine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.levodopaprochlorperazine decreases effects of levodopa by pharmacodynamic antagonism. Avoid or Use Alternate Drug.levodopa inhaledprochlorperazine decreases effects of levodopa inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Phenothiazine/1st generation antipsychotics inhibit dopamine D2 receptors in varying degrees.levoketoconazoleprochlorperazine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.lisurideprochlorperazine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.lofepramineprochlorperazine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.lumefantrineprochlorperazine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.methyl aminolevulinateprochlorperazine, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.methyldopaprochlorperazine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.metoclopramide intranasalprochlorperazine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.prochlorperazine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.moxifloxacinprochlorperazine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.nilotinibprochlorperazine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.octreotideprochlorperazine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.octreotide (Antidote)prochlorperazine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.olopatadine intranasalprochlorperazine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. perphenazineperphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.pramipexoleprochlorperazine decreases effects of pramipexole by pharmacodynamic antagonism. Contraindicated.promazineprochlorperazine and promazine both increase QTc interval. Avoid or Use Alternate Drug.promethazineprochlorperazine and promethazine both increase QTc interval. Avoid or Use Alternate Drug.quinidinequinidine, prochlorperazine. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive cardiac effects.ropiniroleprochlorperazine decreases effects of ropinirole by pharmacodynamic antagonism. Contraindicated.safinamideprochlorperazine decreases effects of safinamide by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Dopamine antagonists may decrease safinamide effects and exacerbate Parkinson disease symptoms.saquinavirsaquinavir, prochlorperazine. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Increased risk of QT prolongation and cardiac arrhythmias.selinexorselinexor, prochlorperazine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sodium oxybateprochlorperazine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.tetrabenazinetetrabenazine and prochlorperazine both decrease QTc interval. Avoid or Use Alternate Drug.thioridazineprochlorperazine and thioridazine both increase QTc interval. Avoid or Use Alternate Drug.tretinoinprochlorperazine, tretinoin. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.tretinoin topicalprochlorperazine, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.trifluoperazineprochlorperazine and trifluoperazine both increase QTc interval. Avoid or Use Alternate Drug.yohimbeyohimbe decreases effects of prochlorperazine by pharmacodynamic antagonism. Contraindicated.ziprasidoneprochlorperazine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (303)abobotulinumtoxinAabobotulinumtoxinA increases effects of prochlorperazine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.aclidiniumaclidinium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.prochlorperazine increases effects of aclidinium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.acrivastineacrivastine and prochlorperazine both increase sedation. Use Caution/Monitor.albiglutideprochlorperazine, albiglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.albuterolprochlorperazine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.alfentanilalfentanil and prochlorperazine both increase sedation. Use Caution/Monitor.alprazolamalprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.amifampridineprochlorperazine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amisulprideprochlorperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.amitriptylineprochlorperazine and amitriptyline both increase QTc interval. Use Caution/Monitor.prochlorperazine and amitriptyline both increase sedation. Use Caution/Monitor.amobarbitalamobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.amoxapineprochlorperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.prochlorperazine and amoxapine both increase QTc interval.